Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 148

Sort by

Sort Order Select

Journal Articles

Inhibition of the MiR-185-PAK6-Mediated Survival and Metabolic Pathways Selectively Targets Drug-Resistant CML Stem/Progenitor Cells

Andrew Wu, BSc, Katharina Rothe, PhD, Min Chen, PhD, Hanyang Lin, PhD, Artem Babaian, PhD, Ryan Yen, BSc, Donna L. Forrest, MD, Xiaoyan Jiang, MD PhD

Blood (2019) 134 (Supplement_1): 4138.

https://doi.org/10.1182/blood-2019-127826

Published: 2019

Journal Articles

A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for Untreated BCR-ABL1-Positive ALL in Older Adults

Marlise Luskin, MDMS, Mark A. Murakami, MDMA,MMSc, Kristen E. Stevenson, MS, Martha Wadleigh, MD, Malgorzata McMasters, MD, Peter Winter, PhD, David M. Weinstock, MD, Richard Stone, MD, Daniel J. DeAngelo, MD PhD

Blood (2019) 134 (Supplement_1): 3879.

https://doi.org/10.1182/blood-2019-125138

Published: 2019

Journal Articles

The Role of Hypoxia on ABL Tyrosine Kinase Inhibitor Resistant Chronic Myeloid Leukemia Cells

Seiichi Okabe, MD PhD, Yuko Tanaka, MD PhD, Mitsuru Moriyama, Akihiko Gotoh, MD PhD

Blood (2019) 134 (Supplement_1): 5369.

https://doi.org/10.1182/blood-2019-129768

Published: 2019

Journal Articles

The ''Gatekeeper'' Mutation T315I in BCR/ABL Confers Additional Oncogenic Activities to Philadelphia Chromosome Positive Leukemia

Usva Zafar, BSc, Mohammed Yusuf, PhD, Rikhia Chakraborty, PhD, El-Nasir M A Lalani, BSc MBChB FRCPath PhDFHEA, Afsar Ali Mian, BSc, MPhil, PhD

Blood (2019) 134 (Supplement_1): 5196.

https://doi.org/10.1182/blood-2019-131694

Published: 2019

Journal Articles

Phase 2 Study of Bosutinib in Japanese Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Naoto Takahashi, MD PhD, Itaru Matsumura, MD PhD, Shin Fujisawa, MD, Kenichi Ishizawa, MD PhD, Takaaki ONO, MD PhD, Emiko Sakaida, MD PhD, Naohiro Sekiguchi, MD PhD, Yusuke Tanetsugu, Kei Fukuhara, Masayuki Ohkura, Yuichiro Koide, Masayuki Hino, MD PhD

Blood (2019) 134 (Supplement_1): 4159.

https://doi.org/10.1182/blood-2019-121809

Published: 2019

Journal Articles

Efficacy and Safety Following Dose Reduction of Bosutinib or Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: Analysis of the Phase 3 BFORE Trial

Tim H. Brummendorf, MD, Carlo Gambacorti-Passerini, MD, Andreas Hochhaus, MD, Jeff H. Lipton, MD PhD, Vamsi Kota, MBBS, Michael W. Deininger, MD PhD, Eric Leip, PhD, Andrea Viqueira, MD, Roxanne Ferdinand, MBBS MFPM, Jorge E. Cortes, MD

Blood (2018) 132 (Supplement 1): 3005.

https://doi.org/10.1182/blood-2018-99-110543

Published: 2018

Journal Articles

Potential IL6R-ADAR1-STAT3 Interplay Promotes Oncogenicity in 1q21(amp) Multiple Myeloma

Phaik Ju Teoh, PhD, Tae-Hoon Chung, Leilei Chen, PhD, Wee Joo Chng, MB ChB, PhD FRCP(UK), FRCPath, FAMS

Blood (2018) 132 (Supplement 1): 4513.

https://doi.org/10.1182/blood-2018-99-118895

Published: 2018

Journal Articles

Interleukin 1 Beta As a Promising Therapeutic Target in ABL Tyrosine Kinase Inhibitor Resistant Chronic Myeloid Leukemia Cells

Seiichi Okabe, MD PhD, Tetsuzo Tauchi, MD PhD, Yuko Tanaka, Kazuma Ohyashiki, MD PhD

Blood (2018) 132 (Supplement 1): 4249.

https://doi.org/10.1182/blood-2018-99-114030

Published: 2018

Journal Articles

Characterizing Population Heterogeneity and Signaling Changes in Chronic Myeloid Leukemia Stem and Progenitor Cells upon Combined Treatment with Imatinib and MEK Inhibitors Using Quantitative Single Cell Phospho-Imaging

Anna Reister Schultz, BS, Thomas Jacob, Christopher A. Eide, Samantha L Savage, Motomi Mori, PhD, Jeffrey W. Tyner, PhD, Cristina E. Tognon, PhD, Tania Q. Vu, Brian J. Druker, MD

Blood (2018) 132 (Supplement 1): 4248.

https://doi.org/10.1182/blood-2018-99-115387

Published: 2018

Journal Articles

Pharmacokinetic and Pharmacogenetic Analysis of Bosutinib in Japanese Patients with Chronic-Phase Chronic Myeloid Leukemia

Akiko Mita, MD, Maiko Abumiya, PhD, Saori Takahashi, Ms, Yoshihiro Kameoka, MD PhD, Masatomo Miura, PhD, Naoto Takahashi, MD

Blood (2018) 132 (Supplement 1): 4271.

https://doi.org/10.1182/blood-2018-99-111905

Published: 2018

Journal Articles

Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) Is Active and Well-Tolerated in Adults with Newly-Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL): Initial Results of a Phase II Trial

Ryan D. Cassaday, MD, Lorinda A. Soma, MD, Olga Sala-Torra, MD, Philip A. Stevenson, MS, Mary-Elizabeth M. Percival, MD, Vivian G. Oehler, MD, Andrei R. Shustov, MD, Pamela S. Becker, MD, Anna B. Halpern, MD, Kelsey-Leigh Garcia, Christen N. Heye, ARNP, Jerald P. Radich, MD, Elihu H. Estey, MD

Blood (2018) 132 (Supplement 1): 1419.

https://doi.org/10.1182/blood-2018-99-110661

Published: 2018

Journal Articles

Real Life Evaluation of Efficacy and Safety of Bosutinib Therapy in Chronic Myeloid Leukemia Patients

Blood (2018) 132 (Supplement 1): 3021.

https://doi.org/10.1182/blood-2018-99-113427

Published: 2018

Journal Articles

Adar-Mediated Aberrant a-to-I RNA Editing Is Driven By 1q Amplification and Contributes to Proteasome Inhibitor Resistance in Multiple Myeloma

Alessandro Lagana, PhD, Violetta Leshchenko, PhD, David Melnekoff, BS, MSc, Itai Beno, PhD, Deepak Perumal, PhD, Jonathan Keats, PhD, Mary DeRome, MS, Jennifer Yesil, MS, Daniel Auclair, PhD, Deepu Madduri, MD, Ajai Chari, MD, Hearn Jay Cho, MD PhD, Bart Barlogie, MD PhD, Sundar Jagannath, MD, Joel Dudley, PhD, Samir Parekh, MD

Blood (2017) 130 (Supplement 1): 268.

https://doi.org/10.1182/blood.V130.Suppl_1.268.268

Published: 2017

Journal Articles

Loss of Ahi-1 Impairs the Self-Renewal Activity of Normal and BCR-ABL + Stem Cells in Vitro and in Vivo

Min Chen, Kevin Lin, PhD, Xiaoyan Jiang, MD PhD

Blood (2017) 130 (Supplement 1): 2516.

https://doi.org/10.1182/blood.V130.Suppl_1.2516.2516

Published: 2017

Journal Articles

Survival of Chronic Myeloid Leukemia Patients in Comparison to General Population in the Tyrosine Kinase Inhibitors Era: A US Population Based Study

Rehan Sarmad, MD MBBS, Omer Jamy, Luciano J. Costa, MD PhD

Blood (2017) 130 (Supplement 1): 2165.

https://doi.org/10.1182/blood.V130.Suppl_1.2165.2165

Published: 2017

Journal Articles

Bosutinib Vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia (CML) in the BFORE Trial: 18 Month Follow-up

Carlo Gambacorti-Passerini, MD, Michael W. Deininger, MD PhD, Michael J. Mauro, MD, Charles Chuah, MD, Dong-Wook Kim, MD PhD, Iryna Dyagil, MDPhD, Natalia Glushko, Dragana Milojkovic, MBBS, PhD, Philipp D. le Coutre, MD, Valentín García Gutiérrez, PhD, Rocco J. Crescenzo, DO, FACOI, Eric Leip, PhD, Nathalie Bardy-Bouxin, PhD, Andrea Hochhaus, Prof. Dr., Timothy H. Brümmendorf, Jorge E. Cortes, MD

Blood (2017) 130 (Supplement 1): 896.

https://doi.org/10.1182/blood.V130.Suppl_1.896.896

Published: 2017

Journal Articles

Second-Line Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CP CML) Resistant or Intolerant to Prior Imatinib: An 8-Year Update

Tim H. Brümmendorf, MD, Carlo Gambacorti-Passerini, MD, Dong-Wook Kim, MD PhD, Yeow Tee Goh, MBBS,MD, Iryna Dyagil, MDPhD, Katia B Pagnano, MD, Árpád Bátai, MD, Anna G Turkina, Prof., MD, Jean M. Aguiar, RN, Eric Leip, PhD, Jorge E. Cortes, MD

Blood (2017) 130 (Supplement 1): 900.

https://doi.org/10.1182/blood.V130.Suppl_1.900.900

Published: 2017

Journal Articles

Therapeutically Targetable Activating c-ABL1 Mutations in Philadelphia Chromosome-Negative Leukemias

Samantha L Savage, Julia E. Maxson, PhD, Christopher A. Eide, Chelsea Jenkins, B.S., Melissa L Abel, Anna M. Reister Schultz, Daniel Bottomly, Beth Wilmot, PhD, Shannon Mcweeney, PhD, Cristina E. Tognon, PhD, Jeffrey W. Tyner, PhD, Brian J. Druker, MD

Blood (2017) 130 (Supplement 1): 3930.

https://doi.org/10.1182/blood.V130.Suppl_1.3930.3930

Published: 2017

Journal Articles

Aurora A Kinase As a Promising Therapeutic Target in Philadelphia Chromosome Positive Leukemia Cells

Seiichi Okabe, MD PhD, Tetsuzo Tauchi, MD, Yuko Tanaka, MD PhD, Kazuma Ohyashiki, MD PhD

Blood (2017) 130 (Supplement 1): 3828.

https://doi.org/10.1182/blood.V130.Suppl_1.3828.3828

Published: 2017

Journal Articles

The Bone Marrow Niche Uses Mir-300 As a Biological Rheostat to Selectively Control Stem Cell-Driven Malignant Hematopoiesis and Innate Anti-Cancer Immunity

Blood (2017) 130 (Supplement 1): 45.

https://doi.org/10.1182/blood.V130.Suppl_1.45.45

Published: 2017

NARROW

Inhibition of the MiR-185-PAK6-Mediated Survival and Metabolic Pathways Selectively Targets Drug-Resistant CML Stem/Progenitor Cells

A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for Untreated BCR-ABL1-Positive ALL in Older Adults

The Role of Hypoxia on ABL Tyrosine Kinase Inhibitor Resistant Chronic Myeloid Leukemia Cells

The ''Gatekeeper'' Mutation T315I in BCR/ABL Confers Additional Oncogenic Activities to Philadelphia Chromosome Positive Leukemia

Phase 2 Study of Bosutinib in Japanese Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Efficacy and Safety Following Dose Reduction of Bosutinib or Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: Analysis of the Phase 3 BFORE Trial

Potential IL6R-ADAR1-STAT3 Interplay Promotes Oncogenicity in 1q21(amp) Multiple Myeloma

Interleukin 1 Beta As a Promising Therapeutic Target in ABL Tyrosine Kinase Inhibitor Resistant Chronic Myeloid Leukemia Cells

Characterizing Population Heterogeneity and Signaling Changes in Chronic Myeloid Leukemia Stem and Progenitor Cells upon Combined Treatment with Imatinib and MEK Inhibitors Using Quantitative Single Cell Phospho-Imaging

Pharmacokinetic and Pharmacogenetic Analysis of Bosutinib in Japanese Patients with Chronic-Phase Chronic Myeloid Leukemia

Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) Is Active and Well-Tolerated in Adults with Newly-Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL): Initial Results of a Phase II Trial

Real Life Evaluation of Efficacy and Safety of Bosutinib Therapy in Chronic Myeloid Leukemia Patients

Adar-Mediated Aberrant a-to-I RNA Editing Is Driven By 1q Amplification and Contributes to Proteasome Inhibitor Resistance in Multiple Myeloma

Loss of Ahi-1 Impairs the Self-Renewal Activity of Normal and BCR-ABL + Stem Cells in Vitro and in Vivo

Survival of Chronic Myeloid Leukemia Patients in Comparison to General Population in the Tyrosine Kinase Inhibitors Era: A US Population Based Study

Bosutinib Vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia (CML) in the BFORE Trial: 18 Month Follow-up

Second-Line Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CP CML) Resistant or Intolerant to Prior Imatinib: An 8-Year Update

Therapeutically Targetable Activating c-ABL1 Mutations in Philadelphia Chromosome-Negative Leukemias

Aurora A Kinase As a Promising Therapeutic Target in Philadelphia Chromosome Positive Leukemia Cells

The Bone Marrow Niche Uses Mir-300 As a Biological Rheostat to Selectively Control Stem Cell-Driven Malignant Hematopoiesis and Innate Anti-Cancer Immunity

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only